UNSPSC 51413207: Sildenafil citrate

This classification denotes a cgmp phosphodiesterase inhibitor with the molecular formula C22H30N6O4S.C6H8O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BW9B0ZE037, chemically known as 1-((3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1h-pyrazolo(4,3-d)pyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl)-4-methylpiperazine citrate (1:1) but more generally known as sildenafil citrate, which bears US NIH Compound Identifier 62853.

UNSPSC 51413207 Sildenafil citrate is a Commodity code capturing individual pharmaceutical products that state and local governments procure for emergency medical services, public health programs, and institutional healthcare delivery. State and local agencies are actively soliciting sildenafil citrate and related pharmaceuticals through emergency services procurement, multistate cooperative purchasing vehicles, and pharmacy benefit programs. Recent activity shows municipal fire rescue departments, state health and human services commissions, and multistate purchasing alliances sourcing both branded and generic pharmaceuticals to support operational and clinical needs. The work involves direct manufacturer supply agreements, wholesaler-managed distribution channels, and compliance-heavy regulatory documentation including FDA certification, cGMP attestation, Drug Supply Chain Security Act (DSCSA) compliance, and OSHA Safety Data Sheets.

Recent opportunities span Florida, Texas, and Minnesota. The City of Tampa's Purchasing Department issued an IFB (Bid No. 26-P-00188) on April 24, 2026, for Advanced Life Support Medications including epinephrine, adenosine, diltiazem, and labetalol for Tampa Fire Rescue, with a response deadline of April 8, 2026, an estimated contract value of $40,000, and a one-year term with options to renew; the solicitation carried a 5 percent Small Local Business Enterprise (SLBE) sheltered market designation. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP for generic multi-source pharmaceuticals and OTC products (S1070000015802) due March 26, 2026, requiring vendors to supply through three authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson) with a July 1, 2026, effective date and a two-year initial term. The Texas Health and Human Services Commission issued a Request for Information (RFI No. HHS0017013) on April 3, 2026, to explore direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization arrangements, signaling exploratory-stage procurement activity that may lead to formal RFP issuance.